KENUP-FOUNDATION
25.1.2021 14:15:10 CET | Business Wire | Press release
Today, AchilleS Vaccines, a biotech company based in Siena (Italy), announced the successful industrial development of a novel monoclonal antibody (mAb) to treat COVID-19. The treatment, patented by Prof Rino Rappuoli’s MAD Lab and developed by AchilleS, could greatly improve access to COVID-19 treatment and has several advantages compared to conventional mAbs: it can be administered intramuscularly, avoiding the risks of hospitalization. Additionally, this mAb is highly potent and the low dosage treatment offers significant health and cost benefits.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210125005376/en/
The AchilleS antibody project ‘mAbCo19’ will now be further tested in the clinic, possibly leading to an emergency market authorization this summer. AchilleS is developing this new therapeutic in cooperation with Toscana Life Sciences (TLS) and several partners, such as ExcelGene, Menarini Biotech and IBI Lorenzini.
"This event, for a small company like ours, is really something to be proud of." says Riccardo Baccheschi, CEO of AchilleS. “By continuing to play our role as an enthusiastic contributor to this potentially market-shaping compound, we will further support and materially coordinate the TLS-sponsored clinical and regulatory processes, hopefully up to market licensing. We hope to actively contribute to the elimination of this pandemic in Europe and in the world and to the return to a normal life for all of us, our collaborators and our loved ones ".
Rino Rappuoli, Director of MAD Lab TLS and inventor of the mAb said: “We are very happy to see that our monoclonal continues to perform extremely well not only against the wild type virus but also against the emerging variants.”
In June 2020 AchilleS received a substantial investment from the EU Malaria Fund (EUMF) to develop vaccines for malaria, other infectious diseases, as well as for the ‘mAbCo19’ project. The EUMF is a public-private partnership providing a novel funding instrument to address market failures in infectious diseases with significant relevance to public health globally.
“The development of this treatment against COVID-19 is very timely and much needed.” says Holm Keller, Executive Chairman of kENUP Foundation. “It shows that small- and medium-sized companies play an important role in the fight against COVID-19 and Malaria. We are grateful for the important work of AchilleS, TLS and Menarini.”
More information can be found at https://www.achillesvaccines.com and https://www.covidx.eu/mabco19 .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210125005376/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Copeland Enters into Exclusive Negotiations to Acquire Dickson, Advancing Cold Chain Leadership29.7.2026 14:00:00 CEST | Press release
Proposed acquisition will expand Copeland’s presence across the healthcare and life sciences cold chain, adding environmental monitoring, compliance expertise and cloud-based monitoring capabilities Copeland, a global leader in compression technologies and controls solutions, today announced its entry into exclusive negotiations towards the purchase of Dickson, a portfolio company of May River Capital and provider of environmental monitoring and cloud-native software solutions for regulated life sciences and healthcare applications. The proposed acquisition will strengthen Copeland’s strategy of enabling an efficient and effective cold chain, building on its existing stationary and in-transit monitoring capabilities to deliver an end-to-end solution that helps healthcare, pharmaceutical and life sciences customers safeguard product integrity, maintain compliance and reduce operational risk. Quality assurance and environmental monitoring represents a large and secularly growing market o
FlexGen’s HybridOS Energy Management System Receives ISO 9001:2015 Certification, Strengthening Its Platform to Serve International Markets29.7.2026 14:00:00 CEST | Press release
New certification builds on FlexGen’s existing compliance with safety and quality standards to support the safe integration and operation of BESS as FlexGen looks to grow its presence in European markets, including UK, France, Spain, Portugal, Germany, Poland, Finland, Sweden, and Ukraine.ISO 9001:2015 certifies the design, development, deployment, and remote software support of the HybridOS energy management system software platform.In addition to earning the ISO 9001:2015 for HybridOS, FlexGen’s platform is aligned with EU grid codes, international safety standards, and utility best practices to meet the highest standards of safety and security. FlexGen Power Systems, LLC. (“FlexGen”), a leading battery energy storage system and energy management software provider, today announced that its HybridOS energy management platform is ISO 9001:2015 certified. ISO 9001:2015 is an internationally recognized standard for quality management, meaning the systems and processes behind HybridOS, fr
Workiva Launches Specialized AI Agents and Intelligence Layer to Advance High-Stakes Reporting29.7.2026 14:00:00 CEST | Press release
Latest AI innovations will help enterprise teams orchestrate and accelerate reporting and compliance workflows Workiva Inc. (NYSE: WK), a leading, audit-ready platform for trust, transparency, and accountability, today announced three purpose-built AI agents and Workiva Knowledge, a persistent intelligence layer grounded in an organization's data, instructions, and content. The agents will help customers in advanced solution tiers accelerate reporting and compliance outcomes with the control and traceability of the Workiva platform. Together, these capabilities offer enterprise teams governed AI at the speed and scale their organizations require. "Finance, sustainability, risk, and compliance teams are moving from execution to orchestration as AI agents take on more of the work, and we're building the platform that makes that transformation possible," said Deepak Bharadwaj, Chief Product Officer of Workiva. "As we evolve the Workiva platform, we're staying true to what our customers ha
Wind Point Partners Announces Final Close of Oversubscribed Fund XI at $3.2 Billion29.7.2026 14:00:00 CEST | Press release
Wind Point Partners (“Wind Point”), a leading Chicago-based private equity firm, today announced the successful closing of its latest fund, Wind Point Partners XI (“Fund XI” or the “Fund”). Fund XI was oversubscribed and exceeded the hard cap, with total commitments of $3.2 billion. This amount includes significant commitments by the General Partner and members of the firm’s Executive Advisor Partner (“EAP”) program, providing strong alignment across all investors in the Fund. Fund XI represents Wind Point’s largest fund to date and its most global and diverse investor base in the firm’s 42-year history. Fund XI received commitments from more than 65 global institutions spanning 17 countries, including pension funds, insurance companies, asset managers, family offices and foundations. Propelled by significant repeat support from existing investors, the efficient fundraise process was completed in under nine months. Founded in 1984, Wind Point has a long history of partnering with top-c
Xpress Genomics Joins Parse Biosciences’ Certified Service Provider Network29.7.2026 14:00:00 CEST | Press release
Stockholm-based service provider adds Evercode to its single cell sequencing offerings Parse Biosciences, the leading provider of scalable and accessible single cell sequencing, and a QIAGEN company, today announced that Xpress Genomics has joined its Certified Service Provider (CSP) program, becoming the first in the Nordic region. The Stockholm-based company will offer Parse's Evercode single cell sequencing portfolio to researchers through its existing sequencing service pipeline. Originating out of the Karolinska Institutet in 2022, Xpress Genomics has built automated, in-house workflows for NGS projects. Joining the CSP program adds Evercode to the company's service offerings, giving its customers direct access to Parse's split-pool single cell technology. "Our customers expect fast, high-quality results," said Christoph Ziegenhain, CEO at Xpress Genomics. "Offering Evercode through our CSP membership gives them a strong option for single cell projects, backed by the same turnarou
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom